PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006   30/04/2025
49,84 USD (+0,65%)
(+0,65%)   30/04/2025

25 april 2025 · PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) · Persbericht

24 april 2025 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

17 april 2025 · PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results · Persbericht

28 maart 2025 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 maart 2025 · PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe · Persbericht

20 maart 2025 · PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies · Persbericht

12 september 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 augustus 2024 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results · Persbericht

30 juli 2024 · PTC Therapeutics Announces Sepiapterin NDA Submission to FDA · Persbericht

25 juli 2024 · PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results · Persbericht

28 juni 2024 · CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review · Persbericht

21 juni 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2024 · Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients · Persbericht

29 mei 2024 · PTC Therapeutics to Participate at Upcoming Investor Conference · Persbericht

28 mei 2024 · PTC Therapeutics Announces Validation of Sepiapterin European MAA · Persbericht

20 mei 2024 · PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation · Persbericht

14 mei 2024 · PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ · Persbericht

2 mei 2024 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

25 april 2024 · PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results · Persbericht

Mijn selecties